Journal of neurology, neurosurgery, and psychiatry
Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity.
Franz Felix Konen, Franziska Axhausen, Stephanie Wolff, Pauline Mühlenbrock, Stefan Gingele, Konstantin Fritz Jendretzky, Sandra Nay, Lea Martha Grote-Levi, Philipp Schwenkenbecher, Sven G Meuth, Thomas Skripuletz, Steffen Pfeuffer
Published: 202610.1136/jnnp-2025-337944
Abstract
BACKGROUND: The optimal strategy after discontinuation of B-cell depleting therapies like ocrelizumab in people with multiple sclerosis (pwMS) remains uncertain, particularly regarding delayed disease reactivation, disability progression and required…
Preview only. Read the full abstract at the source